Clever Culture Systems Limited · ASX:CC5

Clever Culture Systems — Investor Presentation (June 2026)

17 slides from Clever Culture Systems's investor presentation, Jun 23, 2026

  1. Slide 1: Updated Company Presentation

    Clever Culture Systems Ltd 16 Anster St Adelaide SA 5000 www.cleverculturesystems.com ASX:CC5 UPDATED COMPANY PRESENTATION Adelaide, Australia, 23 June 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (CCS or the Company), is pleased to share an updated Company Pres

  2. Slide 2: AI-powered microbiology

    ASX: CC5 For personal use only AI-powered microbiology Revolutionising microbial quality control in pharmaceutical manufacturing Brent Barnes, CEO and Managing Director June 2026 Clever Culture Systems ASX: CC5 1

  3. Slide 3: Disclaimer

    Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. For

  4. Slide 4: Sterile drugs

    Sterile drugs For personal use only Clever Culture Systems. ASX: CC5 3

  5. Slide 5: Problem

    Problem Millions of culture plates are manually Incorrect results costly read and reported annually during pharmaceutical manufacturing High cost of failure For personal use only Up to US$1bn lost revenue1 Failed results in pharmaceutical manufacturing can lead to substantial revenue losses. Catastr

  6. Slide 6: Environmental monitoring today

    Workflow Environmental monitoring today Mandatory process in every pharmaceutical manufacturing facility globally For personal use only Environmental Culture plates monitoring Critical decision point Culture plate reading, reporting. Result to release pharmaceutical product Cleanrooms No Growth (phar

  7. Slide 7: Solution: APAS Automated Plate Assessment System

    Solution Digital disruption Solution: APAS Automated Plate Assessment For personal use only System Cutting edge AI technology Machine learning for microbiology applications Demonstrated performance Extensive scientific data, faster than microbiologist Improved data integrity Automatic data trails and

  8. Slide 8: Environmental monitoring with APAS

    Workflow Environmental monitoring with APAS Mandatory process in every pharmaceutical manufacturing facility globally For personal use only Environmental Culture plates monitoring Critical decision point Automated culture plate reading No Growth >90% Cleanrooms  Batch release (pharmaceutical manufac

  9. Slide 9: Revenue

    Revenue Up to $1.2M revenue per APAS Independence sale4 Includes up-front Capex and Annual Recurring Revenue (ARR) streams For personal use only Product / Approx. Description Revenue Model Service Split APAS® Upfront Capex Laboratory (inc. financing 40% Independence Instrumentation options) APAS Apps

  10. Slide 10: Opportunity

    Opportunity Total addressable pharmaceutical market – $2.8B4 Market Opportunity – sterile pharmaceutical manufacturing Market CAGR growth >8%5 For personal use only 58% Annual SaaS Opportunity $1.6B4 $1.2B4 SaaS / ARR Up-front CAPEX Recurring $230M ARR6 Annual AI software license + hardware Instrume

  11. Slide 11: Sales Strategy: Land & Expand

    Sales Strategy Land & Expand with global pharmaceutical customers How it works Current global pharmaceutical customers For personal use only LAND AstraZeneca Pfizer 1 1-2 instruments at a global 12 instruments – global sites Global pharma customer pharma site Bristol Myers Squibb Novo Nordisk Global

  12. Slide 12: Competition

    Competition Di erent automation approach APAS Independence: Incubation and reading technologies end point reader For personal use only • Requires continuous reading between incubator and imaging platform • Incubation size restricts volume capacity (60-132 plates per day capacity) APAS delivers scale

  13. Slide 13: AstraZeneca Case Study

    Customer AstraZeneca Case Study Enterprise customer – Standardisation across For personal use only multiple global sites 12 instruments • ~1,000 plates per day at large AZ sites purchased and installed • >98% of plates are negative • Occasionally humans make mistakes • Multiple global • APAS resolve

  14. Slide 14: Global installed base of APAS Independence instruments

    Global installed base of APAS® Independence instruments For personal use only Asia-Pac: 7 instruments USA: 11 instruments Europe: 19 instruments • 22 instruments for Pharmaceutical market (units sold + under evaluation + committed order) • 15 instruments for Clinical market APAS sales APAS Service a

  15. Slide 15: Experienced Board and Management

    Experienced Board and Management Focused on expansion into pharmaceutical For personal use only manufacturing industry • Board and Management shareholding 20%+ Brent Barnes Rebecca Wilson CEO and MD, AU Chair, AU Aug-16 start Jul-23 start • International experience with healthcare, technology and ph

  16. Slide 16: Outlook

    Outlook Strong product-market fit evidenced by 8 leading global pharmaceutical companies Land-and-expand commercialisation strategy For personal use only Capital e cient growth model driven by existing customers + qualified pipeline Potential revenue $216M + $19M ARR High margin SaaS model Growing ins

  17. Slide 17: References

    References: For personal use only 1 www.researchandmarkets.com, Global Pharmaceuticals Market Report 2021: Covid-19 Impact and Recovery to 2030. 2 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations 3 https://www.clevercult

Clever Culture Systems — Investor Presentation (June 2026) on 6ix